Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival

Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival

The tumor mutational burden (TMB) has been reported as a predictive marker of the response to immune checkpoint inhibition (ICI) therapy in previous melanoma clinical trials. However, the TMB alone is not sufficient to accurately predict immunotherapy benefit. Additional biomarkers are needed for be...

Full description

Bibliographic Details
Main Authors: Yanmei Gao, Chunhe Yang, Ning He, Guodong Zhao, Jianfei Wang, Yadong Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
tumor mutational burden
tumor heterogeneity
immune checkpoint inhibition
melanoma
benefit score
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.571545/full

Similar Items

Similar Items